Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOAGet Rating) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 75,900 shares, a drop of 40.0% from the April 30th total of 126,600 shares. Based on an average daily volume of 181,000 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC raised its position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOAGet Rating) by 25.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,767 shares of the company’s stock after acquiring an additional 15,400 shares during the quarter. Renaissance Technologies LLC owned approximately 2.44% of Sonoma Pharmaceuticals worth $221,000 as of its most recent SEC filing. 5.78% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Trading Down 3.5 %

Shares of NASDAQ:SNOA opened at $0.94 on Friday. The business has a 50-day moving average price of $0.99 and a 200 day moving average price of $1.28. The company has a market capitalization of $4.37 million, a price-to-earnings ratio of -0.43 and a beta of 1.17. Sonoma Pharmaceuticals has a 12-month low of $0.76 and a 12-month high of $4.19.

About Sonoma Pharmaceuticals

(Get Rating)

Sonoma Pharmaceuticals, Inc engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner.

See Also

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.